(Q36593753)

15 August 2017

1 reference

title

The tumor-draining lymph node as an immune-privileged site (English)

1 reference

15 August 2017

0 references

David H Munn

1

1 reference

PubMed ID

16972902

15 August 2017

Andrew L Mellor

series ordinal

2

1 reference

15 August 2017

1 October 2006

1 reference

15 August 2017

Immunological Reviews

1 reference

15 August 2017

213

1 reference

15 August 2017

146-158

1 reference

Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma

15 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Human tumor antigens recognized by T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

The immunobiology of cancer immunosurveillance and immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Self antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: implications for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Is cancer dangerous to the immune system?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Immune surveillance against a solid tumor fails because of immunological ignorance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Tumor immunity meets autoimmunity: antigen levels and dendritic cell maturation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Regulatory T cells, tumour immunity and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Complementary role of CD4+ T cells and secondary lymphoid tissues for cross-presentation of tumor antigen to CD8+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Antigen presentation to naive CD4 T cells in the lymph node.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Turning on/off tumor-specific CTL response during progressive tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Constitutive presentation of a natural tissue autoantigen exclusively by dendritic cells in the draining lymph node

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Inducible transgenic mice reveal resting dendritic cells as potent inducers of CD8+ T cell tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Immune tolerance after delivery of dying cells to dendritic cells in situ

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

A critical role for Stat3 signaling in immune tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Sentinel lymph nodes show profound downregulation of antigen-presenting cells of the paracortex: implications for tumor biology and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Natural adjuvants: endogenous activators of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Tumor-induced immune dysfunctions caused by myeloid suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Mechanisms and functional significance of tumour-induced dendritic-cell defects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Gr-1+CD115+ Immature Myeloid Suppressor Cells Mediate the Development of Tumor-Induced T Regulatory Cells and T-Cell Anergy in Tumor-Bearing Host

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Inhibition of indoleamine 2,3-dioxygenase augments trinitrobenzene sulfonic acid colitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Prevention of allogeneic fetal rejection by tryptophan catabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

CTLA-4-Ig regulates tryptophan catabolism in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

CDllc+ cells modulate pulmonary immune responses by production of indoleamine 2,3-dioxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Toward the identification of a tolerogenic signature in IDO-competent dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Tumor-infiltrating dendritic cells are potent antigen-presenting cells able to activate T cells and mediate tumor rejection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Both regulatory T cells and antitumor effector T cells are primed in the same draining lymph nodes during tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Tumor-induced L-selectinhigh suppressor T cells mediate potent effector T cell blockade and cause failure of otherwise curative adoptive immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Continuous control of autoimmune disease by antigen-dependent polyclonal CD4+CD25+ regulatory T cells in the regional lymph node

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Infected site-restricted Foxp3+ natural regulatory T cells are specific for microbial antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Natural versus adaptive regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Definition of target antigens for naturally occurring CD4(+) CD25(+) regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Human CD4+CD25+ regulatory T cells share equally complex and comparable repertoires with CD4+CD25- counterparts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Physiologic self antigens rapidly capacitate autoimmune disease-specific polyclonal CD4+ CD25+ regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Recognition of a new ARTC1 peptide ligand uniquely expressed in tumor cells by antigen-specific CD4+ regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Differentiation of T regulatory cells by immature dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Dendritic cells as a tool to induce anergic and regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

The interactions of dendritic cells with antigen-specific, regulatory T cells that suppress autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Specificity of CD4+CD25+ regulatory T cell function in alloimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Tumor-driven evolution of immunosuppressive networks during malignant progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Transforming growth factor-beta in T-cell biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

How do CD4+CD25+ regulatory T cells control autoimmunity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

CD40 ligation releases immature dendritic cells from the control of regulatory CD4+CD25+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Modulation of tryptophan catabolism by regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Human T regulatory cells can use the perforin pathway to cause autologous target cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Regulatory T cells inhibit stable contacts between CD4+ T cells and dendritic cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Cranking the immunologic engine with chemotherapy: using context to drive tumor antigen cross-presentation towards useful antitumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

The new paradigm of T-cell homeostatic proliferation-induced autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Induction of CD4+/CD25+ regulatory T cells by targeting of antigens to immature dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Activation requirements for the induction of CD4+CD25+ T cell suppressor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Activation of Dendritic Cells That Cross-Present Tumor-Derived Antigen Licenses CD8+ CTL to Cause Tumor Eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

CD4+T Cells Are Able to Promote Tumor Growth through Inhibition of Tumor-Specific CD8+T-Cell Responses in Tumor-Bearing Hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00444.X

10.1111/J.1600-065X.2006.00444.X

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference

PubMed ID

16972902